US OptionsDetailed Quotes
QURE241220P20000
- 4.40
- 0.000.00%
15min DelayClose Dec 12 16:00 ET
0.00High0.00Low
4.40Open4.40Pre Close0 Volume5 Open Interest20.00Strike Price0.00Turnover0.00%IV-3.59%PremiumDec 20, 2024Expiry Date4.94Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.49Leverage Ratio--Theta--Rho--Eff Leverage--Vega
uniQure NV Stock Discussion
Sign in to post a comment
$uniQure NV (QURE.US)$ 10$ incoming
1
5
$uniQure NV (QURE.US)$ Wow! gettin closer to actually closing that gap on daily! Color me impressed! Hehehe! Be even more impressed ifn you actually make 19.44? But its looking possible if buy side stays strong! NFA just thinking outloud ![]()
2
$uniQure NV (QURE.US)$ this will fly high too
1
2
$uniQure NV (QURE.US)$ see it when 9.7 but no buy 🙂🙂
1
$uniQure NV (QURE.US)$ hell yeah LG
2
$uniQure NV (QURE.US)$ UniQure Reaches Agreement With FDA On Key Elements Of An Accelerated Approval Pathway For AMT-130
Benzinga· 3 mins ago
-As part of uniQure's Regenerative Medicine Advanced Therapy (RMAT) Type B meeting held in late November, the FDA agreed that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway, avoiding the need for an additional pre-submiss...
Benzinga· 3 mins ago
-As part of uniQure's Regenerative Medicine Advanced Therapy (RMAT) Type B meeting held in late November, the FDA agreed that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway, avoiding the need for an additional pre-submiss...
1
$uniQure NV (QURE.US)$
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
uniQure has reached an agreement with the FDA on key elements for an Accelerated Approval pathway for AMT-130, their Huntington's disease treatment. The FDA agreed that data from ongoing Phase I/II studies compared to natural history external control can serve as the primary basis for a Biologics License Application (BLA), eliminating the need for ad...
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
uniQure has reached an agreement with the FDA on key elements for an Accelerated Approval pathway for AMT-130, their Huntington's disease treatment. The FDA agreed that data from ongoing Phase I/II studies compared to natural history external control can serve as the primary basis for a Biologics License Application (BLA), eliminating the need for ad...
$uniQure NV (QURE.US)$ uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
4 MINUTES AGO, 7:05 AM EST
VIA GLOBENEWSWIRE
4 MINUTES AGO, 7:05 AM EST
VIA GLOBENEWSWIRE
1
$CuriosityStream (CURI.US)$
I went with the wrong Curi! lol, both are good LT though
$uniQure NV (QURE.US)$
I went with the wrong Curi! lol, both are good LT though
$uniQure NV (QURE.US)$
1
$uniQure NV (QURE.US)$ $Apogee Enterprises (APOG.US)$ $Capricor Therapeutics (CAPR.US)$ $noco-noco (NCNC.US)$ $UP Fintech (TIGR.US)$ $JBDI Holdings (JBDI.US)$ $Snail (SNAL.US)$ $Cue Biopharma (CUE.US)$ $Entero Therapeutics (ENTO.US)$ $Power REIT (PW.US)$ $Ford Motor (F.US)$ $Beneficient (BENF.US)$ $Phoenix Motor (PEV.US)$ $Chanson International (CHSN.US)$
📊⚡️📊
📊⚡️📊
3
3
1
No comment yet
Team Crawford : Not today or no time soon will continue to climb over $20 soon
BagHolderAssociation OP Team Crawford : on a half study... try again
Team Crawford BagHolderAssociation OP : We will see who hits their target first $10 or $20.
Team Crawford : $4 away from $20 and you will I am half guessing
BagHolderAssociation OP Team Crawford : I guess 5 away now